

NOS3 Polyclonal Antibody

Catalog # AP71357

Product Information

Application	WB, IHC-P, IF
Primary Accession	P29474
Reactivity	Human, Mouse, Rat
Host	Rabbit
Clonality	Polyclonal
Calculated MW	133275

Additional Information

Gene ID	4846
Other Names	NOS3; Nitric oxide synthase; endothelial; Constitutive NOS; cNOS; EC-NOS; Endothelial NOS; eNOS; NOS type III; NOSIII
Dilution	WB~~WB 1:500-2000, IF 1:50-300, IHC 1:50-300 IHC-P~~WB 1:500-2000, IF 1:50-300, IHC 1:50-300 IF~~1:50~200
Format	Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.09% (W/V) sodium azide.
Storage Conditions	-20°C

Protein Information


Name	NOS3 (HGNC:7876)
Function	Produces nitric oxide (NO) which is implicated in vascular smooth muscle relaxation through a cGMP-mediated signal transduction pathway (PubMed: 1378832). NO mediates vascular endothelial growth factor (VEGF)-induced angiogenesis in coronary vessels and promotes blood clotting through the activation of platelets.
Cellular Location	Cell membrane. Membrane, caveola. Cytoplasm, cytoskeleton. Golgi apparatus. Note=Specifically associates with actin cytoskeleton in the G2 phase of the cell cycle; which is favored by interaction with NOSIP and results in a reduced enzymatic activity
Tissue Location	Platelets, placenta, liver and kidney.

Background


Produces nitric oxide (NO) which is implicated in vascular smooth muscle relaxation through a

cGMP-mediated signal transduction pathway. NO mediates vascular endothelial growth factor (VEGF)-induced angiogenesis in coronary vessels and promotes blood clotting through the activation of platelets.


Images




Immunofluorescence analysis of rat-lung tissue. 1, NOS3 Polyclonal Antibody (red) was diluted at 1:200 (4°C, overnight). 2, Cy3 labeled Secondary antibody was diluted at 1:300 (room temperature, 50 min). 3, Picture B: DAPI (blue) 10 min. Picture A: Target. Picture B: DAPI. Picture C: merge of A+B




Immunofluorescence analysis of rat-lung tissue. 1, NOS3 Polyclonal Antibody (red) was diluted at 1:200 (4°C, overnight). 2, Cy3 labeled Secondary antibody was diluted at 1:300 (room temperature, 50 min). 3, Picture B: DAPI (blue) 10 min. Picture A: Target. Picture B: DAPI. Picture C: merge of A+B




Immunofluorescence analysis of rat-kidney tissue. 1, NOS3 Polyclonal Antibody (red) was diluted at 1:200 (4°C, overnight). 2, Cy3 labeled Secondary antibody was diluted at 1:300 (room temperature, 50 min). 3, Picture B: DAPI (blue) 10 min. Picture A: Target. Picture B: DAPI. Picture C: merge of A+B




Immunofluorescence analysis of rat-kidney tissue. 1, NOS3 Polyclonal Antibody (red) was diluted at 1:200 (4°C, overnight). 2, Cy3 labeled Secondary antibody was diluted at 1:300 (room temperature, 50 min). 3, Picture B: DAPI (blue) 10 min. Picture A: Target. Picture B: DAPI. Picture C: merge of A+B




Immunofluorescence analysis of rat-spleen tissue. 1, NOS3 Polyclonal Antibody (red) was diluted at 1:200 (4°C, overnight). 2, Cy3 labeled Secondary antibody was diluted at 1:300 (room temperature, 50 min). 3, Picture B: DAPI (blue) 10 min. Picture A: Target. Picture B: DAPI. Picture C: merge of A+B




Immunofluorescence analysis of rat-spleen tissue. 1, NOS3 Polyclonal Antibody (red) was diluted at 1:200 (4°C, overnight). 2, Cy3 labeled Secondary antibody was diluted at 1:300 (room temperature, 50 min). 3, Picture B: DAPI (blue) 10 min. Picture A: Target. Picture B: DAPI. Picture C: merge of A+B




Immunohistochemical analysis of paraffin-embedded Human-uterus-cancer tissue. 1, NOS3 Polyclonal Antibody was diluted at 1:200 (4°C, overnight). 2, Sodium citrate pH 6.0 was used for antibody retrieval (>98°C, 20 min). 3, Secondary antibody was diluted at 1:200 (room temperature, 30 min). Negative control was used by secondary antibody only.




Immunohistochemical analysis of paraffin-embedded Human-stomach tissue. 1,NOS3 Polyclonal Antibody was diluted at 1:200(4°C,overnight). 2, Sodium citrate pH 6.0 was used for antibody retrieval(>98°C,20min). 3,Secondary antibody was diluted at 1:200(room temperature, 30min). Negative control was used by secondary antibody only.




Immunohistochemical analysis of paraffin-embedded Rat-testis tissue. 1,NOS3 Polyclonal Antibody was diluted at 1:200(4°C,overnight). 2, Sodium citrate pH 6.0 was used for antibody retrieval(>98°C,20min). 3,Secondary antibody was diluted at 1:200(room temperature, 30min). Negative control was used by secondary antibody only.




Immunohistochemical analysis of paraffin-embedded Rat-brain tissue. 1,NOS3 Polyclonal Antibody was diluted at 1:200(4°C,overnight). 2, Sodium citrate pH 6.0 was used for antibody retrieval(>98°C,20min). 3,Secondary antibody was diluted at 1:200(room temperature, 30min). Negative control was used by secondary antibody only.



Immunohistochemical analysis of paraffin-embedded Rat-spleen tissue. 1,NOS3 Polyclonal Antibody was diluted at 1:200(4°C,overnight). 2, Sodium citrate pH 6.0 was used for antibody retrieval(>98°C,20min). 3,Secondary antibody was diluted at 1:200(room temperature, 30min). Negative control was used by secondary antibody only.




Immunohistochemical analysis of paraffin-embedded Mouse-testis tissue. 1,NOS3 Polyclonal Antibody was diluted at 1:200(4°C,overnight). 2, Sodium citrate pH 6.0 was used for antibody retrieval(>98°C,20min). 3,Secondary antibody was diluted at 1:200(room temperature, 30min). Negative control was used by secondary antibody only.




Western Blot analysis of A549 cells using NOS3 Polyclonal Antibody diluted at 1 : 1000


Western Blot analysis of A549 cells using NOS3 Polyclonal Antibody diluted at 1 : 1000



Western blot analysis of mouse-brain lysis using NOS3 antibody. Antibody was diluted at 1:1000



Western blot analysis of mouse-brain lysis using NOS3 antibody. Antibody was diluted at 1:1000



Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.